The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.
Open accessAbstract
This study was designed to evaluate in healthy volunteers the renal hemodynamic and tubular effects of the orally active angiotensin II receptor antagonist losartan (DuP 753 or MK 954). Losartan or a placebo was administered to 23 subjects maintained on a high-sodium (200 mmol/d) or a low-sodium (50 mmol/d) diet in a randomized, double-blind, crossover study. The two 6-day diet periods were separated by a 5-day washout period. On day 6, the subjects were water loaded, and blood pressure, renal hemodynamics, and urinary electrolyte excretion were measured for 6 hours after a single 100-mg oral dose of losartan (n = 16) or placebo (n = 7). Losartan induced no significant changes in blood pressure, glomerular filtration rate, or renal blood flow in these water-loaded subjects, whatever the sodium diet. In subjects on a low-salt diet, losartan markedly increased urinary sodium excretion from 115 +/- 9 to 207 +/- 21 mumol/min (P < .05). The fractional excretion of endogenous lithium was unchanged, suggesting no effect of losartan on the early proximal tubule in our experimental conditions. Losartan also increased urine flow rate (from 10.5 +/- 0.4 to 13.1 +/- 0.6 mL/min, P < .05); urinary potassium excretion (from 117 +/- 6.9 to 155 +/- 11 mumol/min); and the excretion of chloride, magnesium, calcium, and phosphate. In subjects on a high-salt diet, similar effects of losartan were observed, but the changes induced by the angiotensin II antagonist did not reach statistical significance. In addition, losartan demonstrated significant uricosuric properties with both sodium diets.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blantz, R. C., Konnen, K. S., & Tucker, B. J. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108293 · Cited by 428
Cited by
Effect of longer-term modest salt reduction on blood pressure
He, F. J., Li, J., & MacGregor, G. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004937.pub2 · Cited by 722
Graudal, N. A., Hubeck-Graudal, T., & Jurgens, G. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004022.pub4 · Cited by 620
Angiotensin Receptors and Their Antagonists
Goodfriend, T. L., Elliott, M. E., & Catt, K. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606203342507 · Cited by 558
Effect of Reduced Dietary Sodium on Blood Pressure: A Meta-analysis of Randomized Controlled Trials
Midgley, J. P. (1996) · JAMA · doi:10.1001/jama.1996.03530440070039 · Cited by 544
Graudal, N. A., Galløe, A. M., & Garred, P. (1998) · JAMA · doi:10.1001/jama.279.17.1383 · Cited by 493
Angiotensin II Type 1 Receptor Blockers
Burnier, M. (2001) · Circulation · doi:10.1161/01.cir.103.6.904 · Cited by 485
Self-citationThe impact of serum uric acid on cardiovascular outcomes in the LIFE study
Høieggen, A., Alderman, M. H., Kjeldsen, S. E., Julius, S., Devereux, R. B., de Faire, U., Fyhrquist, F., Ibsen, H., Kristianson, K., Lederballe-Pedersen, O., et al. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00484.x · Cited by 473
Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
Taal, M. W., & Brenner, B. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00031.x · Cited by 439
Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us?
Baker, J. F., Krishnan, E., Chen, L., & Schumacher, H. R. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.03.043 · Cited by 354
Graudal, N. A., Hubeck-Graudal, T., & Jurgens, G. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2011.210 · Cited by 309
Effect of longer-term modest salt reduction on blood pressure
He, F. J., & MacGregor, G. A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004937 · Cited by 300
Rationale for Fixed-Dose Combinations in the Treatment of Hypertension: The Cycle Repeats
Sica, D. A. (2002) · Drugs · doi:10.2165/00003495-200262030-00003 · Cited by 293
Graudal, N. A., Hubeck-Graudal, T., & Jurgens, G. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004022.pub3 · Cited by 170
Brown, N. J., Agirbasli, M., & Vaughan, D. E. (1999) · Hypertension · doi:10.1161/01.hyp.34.2.285 · Cited by 124
Association between arterial properties and renal sodium handling in a general population.
Seidlerová, J., Staessen, J. A., Maillard, M., Nawrot, T., Zhang, H., Bochud, M., Kuznetsova, T., Richart, T., Van Bortel, L. M., Struijker-Boudier, H. A., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000240516.60040.ba · Cited by 25
Self-citationSchmitt, F., Martinez, F., Brillet, G., Nguyen-Khoa, T., Brouard, R., Sissmann, J., Lacour, B., & Grunfeld, J.-P. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199802000-00019 · Cited by 21
Metadata
- Authors
- Burnier, M., Rutschmann, B., Nussberger, J., Versaggi, J., Shahinfar, S., Waeber, B., & Brunner, H. R.
- Venue
- Hypertension
- Published
- 1993-09
- Volume
- 22
- Issue
- 3
- Pages
- 339-347
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2137796067
- Cited by
- 195
- References
- 1
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.